This is a firm-fixed-price delivery order contract awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI) for $679,680.00. The contract is part of a larger In Vivo Toxicology of Tobacco 2015-2020 Indefinite Delivery, Indefinite Quantity (IDIQ) contract. Under this task order, LBERI will conduct an assessment of tobacco products and tobacco product constituents' genetic toxicology using in vitro assays to compare the mutagenicity, cytotoxicity, and genotoxicity of conventional cigarettes versus electronic cigarettes. The contract has no set-aside designation and is scheduled for completion by June 30, 2017.
Generated 4/1/25, 6:45 PM